Yahoo
    NasdaqCM - Delayed Quote USD

    Jasper Therapeutics, Inc. (JSPRW)

    0.0002 -0.0011 (-84.62%)
    At close: September 24 at 3:59:20 PM EDT
    Loading Chart for JSPRW
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Jasper Therapeutics Announces Merger with Kira Pharmaceuticals

    Jasper Therapeutics Announces Merger with Kira Pharmaceuticals
    GlobeNewswire 3mo ago
    Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy

    Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy
    GlobeNewswire 17d ago
    Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants

    Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
    GlobeNewswire 25d ago
    Jasper Therapeutics Announces Key Regulatory and Clinical Appointments

    Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
    GlobeNewswire 1mo ago
    Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

    Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
    GlobeNewswire 1mo ago
    Jasper Therapeutics beats Q2 expectations but shares fall after results

    Jasper Therapeutics beats Q2 expectations but shares fall after results
    InvestorsHub 2mo ago
    Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

    Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
    GlobeNewswire 2mo ago
    Jasper gets a lifeline in merger with immune drugmaker Kira

    Jasper gets a lifeline in merger with immune drugmaker Kira
    BioPharma Dive 3mo ago
    Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight

    Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight
    PR Newswire 4mo ago
    Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now

    Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now
    Zacks 4mo ago
    Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

    Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
    GlobeNewswire 4mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: